{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:39:49Z","timestamp":1787013589050,"version":"build-2736575974"},"reference-count":34,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The efficacy and safety of new psoriatic treatments are confirmed in clinical trials, but such clinical trial data are limited by the number and heterogeneity of patients. Furthermore, the prevalence and characteristics of psoriasis differ among racial groups. Therefore, it is important to obtain real\u2010world evidence in specific regions. To identify the optimal systemic treatment for psoriatic patients in Western Japan, we established the Western Japan Psoriasis Registry (WJPR). This registry is led by a neutral physicians\u2019 league associated with university hospitals, general hospitals, and clinics that specialize in treatment of psoriasis. Systemically treated psoriatic patients who provided written informed consent were enrolled, and data were collected on their background information, several patient\u2010reported outcomes, dermatologists\u2019 objective evaluations, and treatment regimens. Patient enrollment began in 2019, and 1394 patients had been recruited by the end of 2020. The prevalence of psoriatic arthritis was 27.2% and that of pustular psoriasis was 7.5%. The mean body mass index was 24.1\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , and 12% of patients had severe obesity (body mass index \u226530\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ). Major comorbidities were hypertension (35.0%), diabetes (14.1%), and hyperlipidemia (12.2%). Serological data showed that hepatitis B virus surface antigen, anti\u2010hepatitis B virus core antibody, anti\u2010hepatitis C virus antibody, and human T\u2010cell leukemia virus type 1 antibody were detected in 1.1%, 18.0%, 3.1%, and 3.7% of patients, respectively. The most frequently used small\u2010molecule\u2010systemic intervention was apremilast (18.0%), followed by methotrexate (7.7%), etretinate (4.2%), and cyclosporin (3.7%). The most frequently used biologics were interleukin (IL)\u201017 inhibitors (31.8%), followed by IL\u201023 inhibitors (including IL\u201012\/23 inhibitors) (26.7%), and tumor necrosis factor inhibitors (11.1%). The WJPR is the first Japanese prospective observational cohort of psoriatic patients. Annual WJPR updates may provide the incidences of comorbidities such as cardiovascular events or onset of arthritis in systemically treated patients, identify rare complications, and identify the optimal treatment regimens for various psoriatic patients.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.16092","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T08:14:19Z","timestamp":1629792859000},"page":"1709-1718","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Establishment of the Western Japan Psoriasis Registry and first cross\u2010sectional analysis of registered patients"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-9205","authenticated-orcid":false,"given":"Noriko","family":"Tsuruta","sequence":"first","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology Fukuoka University Faculty of Medicine Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Western Japan Inflammatory Disease Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.007"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(02)00142-1"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.01145.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15803"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000076640"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2009.11.002"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13439"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.03.002"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01261.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.012"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10835.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2010.10.016"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13634"},{"issue":"299","key":"e_1_2_7_16_1","first-page":"e16","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti\u2010tumor necrosis factor agents versus classic therapies: Prospective meta\u2010analysis of Psonet registries","volume":"76","author":"Garcia\u2010Doval I","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_7_17_1","first-page":"1210","article-title":"PSOLAR: design, utility, and preliminary results of a prospective, international, disease\u2010based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents","volume":"11","author":"Papp KA","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_18_1","first-page":"960","article-title":"Psoriasis registry in public health hospital","volume":"96","author":"Akaraphanth R","year":"2013","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12240"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14321"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15233"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14834"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15089"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13968"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15156"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14745"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25239"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23181"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-008-2251-0"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40461"},{"key":"e_1_2_7_31_1","article-title":"Effectiveness and safety of non\u2010tumor necrosis factor inhibitor therapy for anti\u2010human T\u2010cell leukemia virus type 1 antibody\u2010positive rheumatoid arthritis","volume":"1","author":"Endo Y","year":"2020","journal-title":"Mod Rheumatol"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1602931"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12112"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14310"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-014-0214-x"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T02:58:45Z","timestamp":1745809125000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/1346-8138.16092"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16092","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"2021-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}